Ryan Priest
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ryan Priest has a total of 125 co-authors. Here are the top co-authors by number of shared publications:
- Marco Colasurdo
Department of Interventional Radiology (M.C.), Oregon Health and Science University, Portland
5 shared publications - Jesse J. Liu
Department of Neurological Surgery, Oregon Health & Science University, Portland (J.J.L.).
4 shared publications - Gary M. Nesbit
Department of Interventional Neuroradiology, Oregon Health and Science University, Portland (G.M.N.).
3 shared publications - Huanwen Chen
Department of Neurosurgery, University of Maryland School of Medicine, Baltimore, MD 21201, USA
3 shared publications - Ajay Malhotra
Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, CT 06520, USA
2 shared publications - Ameer E. Hassan
Department of Neurology, University of Texas Rio Grande Valley, Harlingen, Texas, USA
2 shared publications
Latest Publications
- 1 May 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57 (5) , 1382-1387
Middle Meningeal Artery Embolization Is Associated With Lower Risk of Incident Dementia Among Patients With Subdural Hematoma
BACKGROUND: Nonacute subdural hematoma (NASDH) is associated with cognitive dysfunction and decline. Middle meningeal artery embolization (MMAE) has shown efficacy in reducing NASDH recurrence and promoting hematoma resorption, but its potential impact on long-term cognitive outcomes is unexplored. This study aims to determine whether standalone MMAE is associated with reduced dementia risk compared with conservative management (CM) in dementia-free patients with nonsurgical NASDH. METHODS: This was a multicenter retrospective cohort study using the TriNetX US collaborative research network database. Adult patients with newly diagnosed NASDH who did not undergo surgical drainage were included. Patients with known dementia at the time of NASDH diagnosis were excluded. Patients who underwent standalone MMAE were compared with those who underwent CM only. The primary outcome was new-onset dementia during a 5-year study follow-up period. Secondary outcomes included all-cause mortality. One-to-one propensity score matching was performed to account for confounding and indication bias. Outcomes were compared using time-to-event analyses with Kaplan-Meier curves and Cox proportional hazards models. RESULTS: Of 175 868 patients with nonsurgical NASDH, 1991 underwent MMAE. After propensity score matching, 1972 patients remained in each group with similar baseline characteristics (all absolute standardized differences P P =0.001). CONCLUSIONS: Among nonsurgical, dementia-free patients with NASDH, standalone MMAE was associated with significantly reduced incident dementia risk compared with CM. These findings suggest MMAE may provide neurocognitive benefits beyond preventing hematoma progression, potentially through promoting hematoma resorption and preserving cortical integrity. Prospective studies are needed to confirm these hypothesis-generating observations and establish causality.
- 1 May 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57 (5) , 1382-1387
Middle Meningeal Artery Embolization Is Associated With Lower Risk of Incident Dementia Among Patients With Subdural Hematoma
BACKGROUND: Nonacute subdural hematoma (NASDH) is associated with cognitive dysfunction and decline. Middle meningeal artery embolization (MMAE) has shown efficacy in reducing NASDH recurrence and promoting hematoma resorption, but its potential impact on long-term cognitive outcomes is unexplored. This study aims to determine whether standalone MMAE is associated with reduced dementia risk compared with conservative management (CM) in dementia-free patients with nonsurgical NASDH. METHODS: This was a multicenter retrospective cohort study using the TriNetX US collaborative research network database. Adult patients with newly diagnosed NASDH who did not undergo surgical drainage were included. Patients with known dementia at the time of NASDH diagnosis were excluded. Patients who underwent standalone MMAE were compared with those who underwent CM only. The primary outcome was new-onset dementia during a 5-year study follow-up period. Secondary outcomes included all-cause mortality. One-to-one propensity score matching was performed to account for confounding and indication bias. Outcomes were compared using time-to-event analyses with Kaplan-Meier curves and Cox proportional hazards models. RESULTS: Of 175 868 patients with nonsurgical NASDH, 1991 underwent MMAE. After propensity score matching, 1972 patients remained in each group with similar baseline characteristics (all absolute standardized differences P P =0.001). CONCLUSIONS: Among nonsurgical, dementia-free patients with NASDH, standalone MMAE was associated with significantly reduced incident dementia risk compared with CM. These findings suggest MMAE may provide neurocognitive benefits beyond preventing hematoma progression, potentially through promoting hematoma resorption and preserving cortical integrity. Prospective studies are needed to confirm these hypothesis-generating observations and establish causality.
- Open Access
Intravenous Thrombolysis for Ischemic Stroke Patients with Pituitary Neoplasms: A Nationwide Study and Scoping Review
Objective: The safety of intravenous thrombolysis (IVT) for acute ischemic stroke (AIS) patients with pituitary neoplasms is unclear. This study aims to assess IVT’s safety and efficacy in this patient population. Methods: We reviewed PubMed, Scopus, EMBASE, and Web of Science through July 2025 for reports of IVT administration in AIS patients with pituitary neoplasia. We also performed a retrospective analysis of the Nationwide Readmissions Database (NRD) from 2016 to 2022 to compare outcomes of IVT versus no IVT for AIS patients with pituitary neoplasia, and outcomes of IVT-treated AIS patients with versus without pituitary neoplasia. Outcomes of interest include post-stroke functional status, intracranial hemorrhage (ICH), mortality, and pituitary apoplexy. Multivariate regression analyses were performed to adjust for confounders. Results: The literature review identified 5 AIS patients with pituitary neoplasia, of whom 3/5 (60%) experienced intracranial hemorrhage and none developed apoplexy. In the nationwide analysis of 1,246,750 AIS patients, 1661 (0.13%) had concomitant pituitary neoplasm. Among these patients, IVT was associated with higher odds of functional independence at discharge (adjusted OR 2.46 [95%CI 1.56–3.87]), without increased risk of ICH or in-hospital death (p > 0.05). No cases of pituitary apoplexy were observed. Outcomes among all IVT-treated AIS patients did not differ between those with and without pituitary neoplasms (all p > 0.05). Interpretation: Only five cases of IVT for AIS patients with pituitary neoplasia were identified, highlighting a striking lack of clinical data. In a large U.S. cohort of AIS patients, IVT was associated with improved hospitalization outcomes without increased risk of ICH or pituitary apoplexy.
Open AccessIntravenous Thrombolysis for Ischemic Stroke Patients with Pituitary Neoplasms: A Nationwide Study and Scoping Review
Objective: The safety of intravenous thrombolysis (IVT) for acute ischemic stroke (AIS) patients with pituitary neoplasms is unclear. This study aims to assess IVT’s safety and efficacy in this patient population. Methods: We reviewed PubMed, Scopus, EMBASE, and Web of Science through July 2025 for reports of IVT administration in AIS patients with pituitary neoplasia. We also performed a retrospective analysis of the Nationwide Readmissions Database (NRD) from 2016 to 2022 to compare outcomes of IVT versus no IVT for AIS patients with pituitary neoplasia, and outcomes of IVT-treated AIS patients with versus without pituitary neoplasia. Outcomes of interest include post-stroke functional status, intracranial hemorrhage (ICH), mortality, and pituitary apoplexy. Multivariate regression analyses were performed to adjust for confounders. Results: The literature review identified 5 AIS patients with pituitary neoplasia, of whom 3/5 (60%) experienced intracranial hemorrhage and none developed apoplexy. In the nationwide analysis of 1,246,750 AIS patients, 1661 (0.13%) had concomitant pituitary neoplasm. Among these patients, IVT was associated with higher odds of functional independence at discharge (adjusted OR 2.46 [95%CI 1.56–3.87]), without increased risk of ICH or in-hospital death (p > 0.05). No cases of pituitary apoplexy were observed. Outcomes among all IVT-treated AIS patients did not differ between those with and without pituitary neoplasms (all p > 0.05). Interpretation: Only five cases of IVT for AIS patients with pituitary neoplasia were identified, highlighting a striking lack of clinical data. In a large U.S. cohort of AIS patients, IVT was associated with improved hospitalization outcomes without increased risk of ICH or pituitary apoplexy.
- Top Cited PapersOpen Access
- 1 August 2025
- Published by Wolters Kluwer Health in Stroke
- Vol. 56 (8) , 1980-1990
SUMMIT MAX: A Randomized Trial of the Super Large Bore HiPoint Reperfusion System Versus Vecta System for Aspiration Thrombectomy
BACKGROUND: Rapid and complete recanalization is a primary goal in the endovascular treatment of large vessel occlusion stroke. The effectiveness and safety of super large bore aspiration catheters (0.088″ inner diameter) for the treatment of large vessel occlusion stroke have not been demonstrated in a randomized trial. METHODS: SUMMIT MAX (A Prospective, Randomized, Controlled, Interventional Clinical Trial to Evaluate the Safety and Effectiveness of the Route 92 Medical MonoPoint Reperfusion System for Aspiration Embolectomy in Acute Ischemic Stroke Patients) was a prospective, randomized, controlled, open-label clinical trial of patients with internal carotid artery and middle cerebral artery M1 occlusions, comparing the super large bore HiPoint Reperfusion system (Route 92 Medical) to the Vecta Aspiration system (Stryker Neurovascular). We hypothesized that the effectiveness and safety of the HiPoint reperfusion system were noninferior (12.5% noninferiority margin) to the Vecta Aspiration system. The primary effectiveness end point was successful reperfusion, defined as modified Treatment in Cerebral Infarction≥2b as adjudicated by an independent core lab, using only the assigned study device, with any use of a nonstudy device before or after the use of study device defined as failure. The primary safety end point was symptomatic intracranial hemorrhage within 24 hours (−8/+24) post-procedure. RESULTS: There were 250 patients enrolled of whom 166 met the criteria for the modified intent-to-treat population: 89 in HiPoint and 77 in Vecta. The median age was 69 years; 54.2% were female. Successful reperfusion with any adjunctive therapy counted as a failure was 77.5% (69/89) in the HiPoint group versus 50.6% (39/77) in the Vecta group ( P P =0.75). CONCLUSIONS: In this randomized trial of patients with anterior large vessel occlusion, the super large bore HiPoint system was noninferior to the Vecta system in achieving successful reperfusion, with a similar safety profile. This study supports the super large bore HiPoint system for mechanical thrombectomy. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05018650.
- 1 August 2025
- Published by Wolters Kluwer Health in Stroke
- Vol. 56 (8) , 1980-1990
Top Cited PapersOpen AccessSUMMIT MAX: A Randomized Trial of the Super Large Bore HiPoint Reperfusion System Versus Vecta System for Aspiration Thrombectomy
BACKGROUND: Rapid and complete recanalization is a primary goal in the endovascular treatment of large vessel occlusion stroke. The effectiveness and safety of super large bore aspiration catheters (0.088″ inner diameter) for the treatment of large vessel occlusion stroke have not been demonstrated in a randomized trial. METHODS: SUMMIT MAX (A Prospective, Randomized, Controlled, Interventional Clinical Trial to Evaluate the Safety and Effectiveness of the Route 92 Medical MonoPoint Reperfusion System for Aspiration Embolectomy in Acute Ischemic Stroke Patients) was a prospective, randomized, controlled, open-label clinical trial of patients with internal carotid artery and middle cerebral artery M1 occlusions, comparing the super large bore HiPoint Reperfusion system (Route 92 Medical) to the Vecta Aspiration system (Stryker Neurovascular). We hypothesized that the effectiveness and safety of the HiPoint reperfusion system were noninferior (12.5% noninferiority margin) to the Vecta Aspiration system. The primary effectiveness end point was successful reperfusion, defined as modified Treatment in Cerebral Infarction≥2b as adjudicated by an independent core lab, using only the assigned study device, with any use of a nonstudy device before or after the use of study device defined as failure. The primary safety end point was symptomatic intracranial hemorrhage within 24 hours (−8/+24) post-procedure. RESULTS: There were 250 patients enrolled of whom 166 met the criteria for the modified intent-to-treat population: 89 in HiPoint and 77 in Vecta. The median age was 69 years; 54.2% were female. Successful reperfusion with any adjunctive therapy counted as a failure was 77.5% (69/89) in the HiPoint group versus 50.6% (39/77) in the Vecta group ( P P =0.75). CONCLUSIONS: In this randomized trial of patients with anterior large vessel occlusion, the super large bore HiPoint system was noninferior to the Vecta system in achieving successful reperfusion, with a similar safety profile. This study supports the super large bore HiPoint system for mechanical thrombectomy. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05018650.
- 2 April 2025
- Published by Springer Nature in Neuroradiology
- Vol. 67 (7) , 1827-1836
Development of a machine learning model to predict changes in neuroimaging profiles among acute ischemic stroke patients following delayed transfer for endovascular thrombectomy
Introduction Endovascular thrombectomy (EVT) patient selection depends on neuroimaging. However, interhospital transfer delays can lead to neuroimaging changes, whether and when repeat imaging is necessary are unclear. Herein, we develop a machine learning model (MLM) to predict vessel recanalization, ischemia progression, and imaging stability for EVT candidates who experience delayed interhospital transfer. Methods This retrospective study included EVT candidates with internal carotid or middle cerebral artery occlusion stroke transferred 1.5–6.0 h after initial imaging. Clinical and radiographic data were collected. A gradient-boosted tree-based MLM (XGBoost) was trained and optimized on 66% of the cohort (randomly selected) using 10-fold cross-validation, and the MLM was independently validated on the remaining, untouched 33% of the study cohort. Model performance was assessed using areas under the receiver operating characteristics curve (AUC) for discrimination, F1 scores for precision/recall, and Brier scores for calibration. Results Among 317 patients, 69.4% had stable imaging, 14.5% showed ischemia progression (ASPECTS drop ≥ 2), and 16.1% had vessel recanalization. The MLM was developed and optimized in the training cohort (n = 212). NIH stroke scale improvement, onset-to-imaging time, intravenous thrombolysis, initial ASPECTS, and collateral score were important features. In the validation cohort (n = 105), the MLM achieved AUCs of 0.81 (95%CI 0.72–0.90) for imaging stability, 0.82 (95%CI 0.72–0.91) for ischemia progression, and 0.89 (95%CI 0.77-1.00) for vessel recanalization. F1 scores were 0.87 and 0.95 for stability and no recanalization, with Brier scores of 0.17 and 0.08, respectively. Conclusion Our MLM accurately predicts imaging changes among EVT candidates who experienced transfer delays.
- 2 April 2025
- Published by Springer Nature in Neuroradiology
- Vol. 67 (7) , 1827-1836
Development of a machine learning model to predict changes in neuroimaging profiles among acute ischemic stroke patients following delayed transfer for endovascular thrombectomy
Introduction Endovascular thrombectomy (EVT) patient selection depends on neuroimaging. However, interhospital transfer delays can lead to neuroimaging changes, whether and when repeat imaging is necessary are unclear. Herein, we develop a machine learning model (MLM) to predict vessel recanalization, ischemia progression, and imaging stability for EVT candidates who experience delayed interhospital transfer. Methods This retrospective study included EVT candidates with internal carotid or middle cerebral artery occlusion stroke transferred 1.5–6.0 h after initial imaging. Clinical and radiographic data were collected. A gradient-boosted tree-based MLM (XGBoost) was trained and optimized on 66% of the cohort (randomly selected) using 10-fold cross-validation, and the MLM was independently validated on the remaining, untouched 33% of the study cohort. Model performance was assessed using areas under the receiver operating characteristics curve (AUC) for discrimination, F1 scores for precision/recall, and Brier scores for calibration. Results Among 317 patients, 69.4% had stable imaging, 14.5% showed ischemia progression (ASPECTS drop ≥ 2), and 16.1% had vessel recanalization. The MLM was developed and optimized in the training cohort (n = 212). NIH stroke scale improvement, onset-to-imaging time, intravenous thrombolysis, initial ASPECTS, and collateral score were important features. In the validation cohort (n = 105), the MLM achieved AUCs of 0.81 (95%CI 0.72–0.90) for imaging stability, 0.82 (95%CI 0.72–0.91) for ischemia progression, and 0.89 (95%CI 0.77-1.00) for vessel recanalization. F1 scores were 0.87 and 0.95 for stability and no recanalization, with Brier scores of 0.17 and 0.08, respectively. Conclusion Our MLM accurately predicts imaging changes among EVT candidates who experienced transfer delays.
- 6 January 2025
- Published by Elsevier in Clinical Neurology and Neurosurgery
- Vol. 249, 108722
The PANDA score: External validation and modification of a simple upfront prediction tool for poor outcomes despite successful stroke thrombectomy
- 6 January 2025
- Published by Elsevier in Clinical Neurology and Neurosurgery
- Vol. 249, 108722
The PANDA score: External validation and modification of a simple upfront prediction tool for poor outcomes despite successful stroke thrombectomy
- Open Access
- 25 June 2022
- Published by Oxford University Press (OUP) in Neuro-Oncology Advances
- Vol. 4 (1) , vdac104
Safety of intra-arterial chemotherapy with or without osmotic blood–brain barrier disruption for the treatment of patients with brain tumors
Intra-arterial administration of chemotherapy with or without osmotic blood–brain barrier disruption enhances delivery of therapeutic agents to brain tumors. The aim of this study is to evaluate the safety of these procedures. Retrospectively collected data from a prospective database of consecutive patients with primary and metastatic brain tumors who received intra-arterial chemotherapy without osmotic blood–brain barrier disruption (IA) or intra-arterial chemotherapy with osmotic blood–brain barrier disruption (IA/OBBBD) at Oregon Health and Science University (OHSU) between December 1997 and November 2018 is reported. Chemotherapy-related complications are detailed per Common Terminology Criteria for Adverse Events (CTCAE) guidelines. Procedure-related complications are grouped as major and minor. 4939 procedures (1102 IA; 3837 IA/OBBBD) were performed on 436 patients with various pathologies (primary central nervous system lymphoma [26.4%], glioblastoma [18.1%], and oligodendroglioma [14.7%]). Major procedure-related complications (IA: 12, 1%; IA/OBBBD: 27, 0.7%; P = .292) occurred in 39 procedures including 3 arterial dissections requiring intervention, 21 symptomatic strokes, 3 myocardial infarctions, 6 cervical cord injuries, and 6 deaths within 3 days. Minor procedure-related complications occurred in 330 procedures (IA: 41, 3.7%; IA/OBBBD: 289, 7.5%; P = .001). Chemotherapy-related complications with a CTCAE attribution and grade higher than 3 was seen in 359 (82.3%) patients. We provide safety and tolerability data from the largest cohort of consecutive patients who received IA or IA/OBBBD. Our data demonstrate that IA or IA/OBBBD safely enhance drug delivery to brain tumors and brain around the tumor.
- 25 June 2022
- Published by Oxford University Press (OUP) in Neuro-Oncology Advances
- Vol. 4 (1) , vdac104
Open AccessSafety of intra-arterial chemotherapy with or without osmotic blood–brain barrier disruption for the treatment of patients with brain tumors
Intra-arterial administration of chemotherapy with or without osmotic blood–brain barrier disruption enhances delivery of therapeutic agents to brain tumors. The aim of this study is to evaluate the safety of these procedures. Retrospectively collected data from a prospective database of consecutive patients with primary and metastatic brain tumors who received intra-arterial chemotherapy without osmotic blood–brain barrier disruption (IA) or intra-arterial chemotherapy with osmotic blood–brain barrier disruption (IA/OBBBD) at Oregon Health and Science University (OHSU) between December 1997 and November 2018 is reported. Chemotherapy-related complications are detailed per Common Terminology Criteria for Adverse Events (CTCAE) guidelines. Procedure-related complications are grouped as major and minor. 4939 procedures (1102 IA; 3837 IA/OBBBD) were performed on 436 patients with various pathologies (primary central nervous system lymphoma [26.4%], glioblastoma [18.1%], and oligodendroglioma [14.7%]). Major procedure-related complications (IA: 12, 1%; IA/OBBBD: 27, 0.7%; P = .292) occurred in 39 procedures including 3 arterial dissections requiring intervention, 21 symptomatic strokes, 3 myocardial infarctions, 6 cervical cord injuries, and 6 deaths within 3 days. Minor procedure-related complications occurred in 330 procedures (IA: 41, 3.7%; IA/OBBBD: 289, 7.5%; P = .001). Chemotherapy-related complications with a CTCAE attribution and grade higher than 3 was seen in 359 (82.3%) patients. We provide safety and tolerability data from the largest cohort of consecutive patients who received IA or IA/OBBBD. Our data demonstrate that IA or IA/OBBBD safely enhance drug delivery to brain tumors and brain around the tumor.
- Open Access
- 1 May 2021
- Published by Wolters Kluwer Health in Stroke
- Vol. 52 (5) , 1534-1544
New Class of Radially Adjustable Stentrievers for Acute Ischemic Stroke
Background and Purpose: The Tigertriever is a novel, radially adjustable, fully visible, stentriever that permits the operator to align radial expansion with target vessel diameters. This multicenter trial compared the Tigertriever’s effectiveness and safety compared with established stent retrievers. Methods: Single arm, prospective, multicenter trial comparing the Tigertriever to efficacy and safety performance goals derived from outcomes in 6 recent pivotal studies evaluating the Solitaire and Trevo stent-retriever devices with a lead-in and a main-study phase. Patients were enrolled if they had acute ischemic stroke with National Institutes of Health Stroke Scale score ≥8 due to large vessel occlusion within 8 hours of onset. The primary efficacy end point was successful reperfusion, defined as core laboratory-adjudicated modified Thrombolysis in Cerebral Ischemia score 2b-3 within 3 passes of the Tigertriever. The primary safety end point was a composite of 90-day all-cause mortality and symptomatic intracranial hemorrhage. Secondary efficacy end points included 3-month good clinical outcome (modified Rankin Scale score 0–2) and first-pass successful reperfusion. Results: Between May 2018 and March 2020, 160 patients (43 lead-in, 117 main phase) at 17 centers were enrolled and treated with the Tigertriever. The primary efficacy end point was achieved in 84.6% in the main-study phase group compared with the 63.4% performance goal and the 73.4% historical rate (noninferiority P P P =0.004; superiority P =0.57). Good clinical outcome was achieved in 58% at 90 days. Conclusions: The Tigertriever device was shown to be highly effective and safe compared with Trevo and Solitaire devices to remove thrombus in patients with large-vessel occlusive stroke eligible for mechanical thrombectomy. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03474549.
- 1 May 2021
- Published by Wolters Kluwer Health in Stroke
- Vol. 52 (5) , 1534-1544
Open AccessNew Class of Radially Adjustable Stentrievers for Acute Ischemic Stroke
Background and Purpose: The Tigertriever is a novel, radially adjustable, fully visible, stentriever that permits the operator to align radial expansion with target vessel diameters. This multicenter trial compared the Tigertriever’s effectiveness and safety compared with established stent retrievers. Methods: Single arm, prospective, multicenter trial comparing the Tigertriever to efficacy and safety performance goals derived from outcomes in 6 recent pivotal studies evaluating the Solitaire and Trevo stent-retriever devices with a lead-in and a main-study phase. Patients were enrolled if they had acute ischemic stroke with National Institutes of Health Stroke Scale score ≥8 due to large vessel occlusion within 8 hours of onset. The primary efficacy end point was successful reperfusion, defined as core laboratory-adjudicated modified Thrombolysis in Cerebral Ischemia score 2b-3 within 3 passes of the Tigertriever. The primary safety end point was a composite of 90-day all-cause mortality and symptomatic intracranial hemorrhage. Secondary efficacy end points included 3-month good clinical outcome (modified Rankin Scale score 0–2) and first-pass successful reperfusion. Results: Between May 2018 and March 2020, 160 patients (43 lead-in, 117 main phase) at 17 centers were enrolled and treated with the Tigertriever. The primary efficacy end point was achieved in 84.6% in the main-study phase group compared with the 63.4% performance goal and the 73.4% historical rate (noninferiority P P P =0.004; superiority P =0.57). Good clinical outcome was achieved in 58% at 90 days. Conclusions: The Tigertriever device was shown to be highly effective and safe compared with Trevo and Solitaire devices to remove thrombus in patients with large-vessel occlusive stroke eligible for mechanical thrombectomy. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03474549.
- 1 August 2020
- Published by Elsevier in World Neurosurgery
- Vol. 140, 262-266
Embolization of Basilar Tip Aneurysm via Ascending Cervical Artery
- 1 August 2020
- Published by Elsevier in World Neurosurgery
- Vol. 140, 262-266
Embolization of Basilar Tip Aneurysm via Ascending Cervical Artery
- 14 May 2020
- Published by Georg Thieme Verlag KG in Seminars in Interventional Radiology
- Vol. 37 (02) , 132-139
Carotid Revascularization: Current Practice and Future Directions
Carotid stenosis is responsible for approximately 15% of ischemic strokes. Carotid revascularization significantly decreases patients' stroke risk. Carotid endarterectomy has first-line therapy for moderate-to-severe carotid stenosis after a series of pivotal randomized controlled trials were published almost 30 years ago. Revascularization with carotid stenting has become a popular and effective alternative in a select subpopulation of patients. We review the current state of the literature regarding revascularization indications, patient selection, advantages of each revascularization approach, timing of intervention, and emerging interventional techniques, such as transcarotid artery revascularization.
- 14 May 2020
- Published by Georg Thieme Verlag KG in Seminars in Interventional Radiology
- Vol. 37 (02) , 132-139
Carotid Revascularization: Current Practice and Future Directions
Carotid stenosis is responsible for approximately 15% of ischemic strokes. Carotid revascularization significantly decreases patients' stroke risk. Carotid endarterectomy has first-line therapy for moderate-to-severe carotid stenosis after a series of pivotal randomized controlled trials were published almost 30 years ago. Revascularization with carotid stenting has become a popular and effective alternative in a select subpopulation of patients. We review the current state of the literature regarding revascularization indications, patient selection, advantages of each revascularization approach, timing of intervention, and emerging interventional techniques, such as transcarotid artery revascularization.